Cargando…
Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there...
Autores principales: | Pape, Anke, Kielstein, Jan T., Krüger, Tillman, Fühner, Thomas, Brunkhorst, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046512/ https://www.ncbi.nlm.nih.gov/pubmed/33870077 http://dx.doi.org/10.1055/s-0041-1727121 |
Ejemplares similares
-
Hemofiltration with the Seraph(®) 100 Microbind(®) Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients
por: Kielstein, Jan T., et al.
Publicado: (2021) -
In vitro elimination of anti-infective drugs by the Seraph(®) 100 Microbind(®) affinity blood filter
por: Schmidt, Julius J, et al.
Publicado: (2020) -
Interim analysis of the COSA (COVID-19 patients treated with the Seraph(®) 100 Microbind(®) Affinity filter) registry
por: Schmidt, Julius J, et al.
Publicado: (2021) -
Staphylococcus aureus binding to Seraph(®) 100 Microbind(®) Affinity Filter: Effects of surface protein expression and treatment duration
por: Seffer, Malin-Theres, et al.
Publicado: (2023) -
A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19
por: Chitty, Stephen A., et al.
Publicado: (2022)